Molecular Selection, Modification and Development of Therapeutic Oligonucleotide Aptamers
Monoclonal antibodies are the dominant agents used in inhibition of biological target molecules for disease therapeutics, but there are concerns of immunogenicity, production, cost and stability. Oligonucleotide aptamers have comparable affinity and specificity to targets with monoclonal antibodies...
Main Authors: | Yuanyuan Yu, Chao Liang, Quanxia Lv, Defang Li, Xuegong Xu, Baoqin Liu, Aiping Lu, Ge Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/17/3/358 |
Similar Items
-
Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases
by: Valentina Giudice, et al.
Published: (2020-05-01) -
The Application of Microfluidic Technologies in Aptamer Selection
by: Yang Liu, et al.
Published: (2021-09-01) -
Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy
by: Hongguang Sun, et al.
Published: (2014-01-01) -
Recent Advances in Oligonucleotide Therapeutics in Oncology
by: Haoyu Xiong, et al.
Published: (2021-03-01) -
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
by: Suzan M Hammond, et al.
Published: (2021-04-01)